Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Esmée de Baat

PhD student
Esmée de Baat
Esmée de Baat
Cardiotoxicity in childhood cancer survivors
Phone 088 97 97 25 192

Survival of childhood cancer has improved importantly. Despite this success, childhood cancer survivors (CCS) have an increased risk of serious cardiac diseases as result of cardiotoxic cancer treatment. These cardiac diseases are related to increased morbidity and non-cancer mortality. As part of the Dutch LATER study in approximately 1400 CCS en 250 siblings clinical and cardiac assessments (blood samples, electrocardiography, echocardiography) was performed between 2016 and 2020. The goals of my PhD are to identify new risk factors and to provide extended evidence for recommendation on cardiotoxicity surveillance. My projects focus on electrocardiography as detection method, iron overload and guideline development.
Currently, I coordinate the development of an international clinical practice guideline for the drug dexrazoxane within the international Guideline Harmonization Group (ighg.org). Dexrazoxane may have a protective effect on the heart during treatment with anthracyclines. It focuses on the use of dexrazoxane during anthracycline treatment in children, young adults and adolescents based on the available literature.

Side activities: part of the committee responsible for scientific internships of students within Group Kremer.

Supervisor(s): L.C.M. Kremer, A.M.C. Mavinkurve-Groothuis, E.A.M. Feijen, L. Kapusta



New guideline for medication against heart damage in children with cancer


de Baat et al. Hartschade als een laat effect van de behandeling van kinderkanker. NTvO, May 2020.

Leerink JM, Baat ECd, Feijen EAM, Bellersen L, Dalen ECv, Grotenhuis HB, Kapusta L, Kok WEM, Loonen J, Pal HJHvd, Pluijm SMF, Teske AJ, Mavinkurve-Groothuis AMC, Merkx R and Kremer LCM. Cardiac Disease in Childhood Cancer Survivors. JACC: CardioOncology. 2020;2:363-378.

  • Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines

    • dec. 2022
    • Esmée C., de Baat, et al
    • The Lancet Child and Adolescent Health
  • Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines

    • sep. 2022
    • Esmée C., de Baat, et al
    • Cochrane Database of Systematic Reviews
  • Electrocardiographic abnormalities in childhood cancer survivors treated with cardiotoxic therapy

    • aug. 2022
    • Esmée C., de Baat, et al
    • Pediatric Blood and Cancer
  • Candidate Plasma Biomarkers to Detect Anthracycline-Related Cardiomyopathy in Childhood Cancer Survivors

    • jul. 2022
    • Jan M, Leerink, et al
    • Journal of the American Heart Association
  • Asymptomatic systolic dysfunction on contemporary echocardiography in anthracycline-treated long-term childhood cancer survivors

    • apr. 2022
    • Remy, Merkx, et al
    • Journal of cancer survivorship : research and practice
View all publications